Skip to content

A Clinical Study on fospropofol disodium, remimazolam, and propofol in General Anesthesia for Elderly Patients

A Clinical Study on fospropofol disodium, remimazolam, and propofol in General Anesthesia for Elderly Patients

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126119
Enrollment
Unknown
Registered
2026-06-04
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None

Interventions

Propofol group: During general anesthesia induction, propofol (2 mg/kg) was administered intravenously at a constant rate over 1 minute by Investigator B.
Remimazolam group:During general anesthesia induction, remimazolam (0.3 mg/kg) was administered intravenously at a constant rate over 1 minute by Investigator B.
Fospropofol disodium:During general anesthesia induction, disodium fospropofol (15 mg/kg) was administered intravenously at a constant rate over 1 minute by Investigator B.

Sponsors

Fuyang People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age = 65 years, with a Body Mass Index (BMI) ranging from 18 to 28 kg/m². 2.American Society of Anesthesiologists (ASA) physical status I–III. 3.Patients undergoing elective surgery with endotracheal intubation under general anesthesia, with an expected duration of less than 3 hours. 4.Patients who understood the study protocol, voluntarily participated, and signed the informed consent form.

Exclusion criteria

Exclusion criteria: 1.Patients with a known allergy to the anesthetic agents used in this study, or those with a history of severe allergy or a family history of such allergies. 2.Patients with a suspected difficult airway or anticipated difficult intubation. 3.Patients with a history of long-term use of sedatives, analgesics, or non-steroidal anti-inflammatory drugs. 4.Patients with a history of psychiatric disorders, or those with severe dysfunction of the heart, lung, liver, kidney, or brain 5.Patients deemed unsuitable for participation in this study by the investigators.

Design outcomes

Primary

MeasureTime frame
Area under the curve of blood pressure and compared to baseline within 10 minutes after induction;Area under the curve of heart rate from baseline to 10 minutes post-induction;

Secondary

MeasureTime frame
Sedation/anesthesia after induction (MOAA/S score = 1);Time to BIS = 60 after induction;Quality of recovery;Adverse events;

Countries

China

Contacts

Public ContactDai Chenxu

Fuyang People's Hospital

158537084@qq.com+86 152 0558 0789

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026